| Issue Date |
Title |
Author(s) |
| 2017 |
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China |
Shi, Yuankai;Jia, Bo;Xu, Wei;Li, Wenyu;Liu, Ting;Liu, Peng;Zhao, Weili;Zhang, Huilai;Sun, Xiuhua;Yang, Haiyan;Zhang, Xi;Jin, Jie;Jin, Zhengming;Li, Zhiming;Qiu, Lugui;Dong, Mei;Huang, Xiaobing;Luo, Yi;Wang, Xiaodong;Wang, Xin;Wu, Jianqiu;Xu, Jingyan;Yi, Pingyong;Zhou, Jianfeng;He, Hongming;Liu, Lin;Shen, Jianzhen;Tang, Xiaoqiong;Wang, Jinghua;Yang, Jianmin;Zeng, Qingshu;Zhang, Zhihui;Cai, Zhen;Chen, Xiequn;Ding, Kaiyang;Hou, Ming;Huang, Huiqiang;Li, Xiaoling;Liang, Rong;Liu, Qifa;Song, Yuqin;Su, Hang;Gao, Y |
| May-2020 |
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1 |
Nowakowski, Grzegorz S.;Zhu, Jun;Zhang, Qingyuan;Brody, Joshua;Sun, Xiuhua;Maly, Joseph;Song, Yuqin;Rizvi, Syed;Song, Yongping;Lansigan, Frederick;Jing, Hongmei;Cao, Junning;Lue, Jennifer K.;Luo, Wen;Zhang, Lei;Li, Ling;Han, Isabel;Sun, Joan;Jivani, Manoj;Liu, Young;Heineman, Thomas;Smith, Stephen D. |
| 20-May-2021 |
A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL). |
Song, Yuqin;Zhou, Keshu;Jin, Chuan;Qian, Zhengzi;Hou, Ming;Fan, Lei;Li, Fei;Ding, Kaiyang;Zhou, Hui;Li, Xiaoling;Chen, Bing;Sun, Xiuhua;Song, Xianmin;Jiang, Ming;Zhang, Qingyuan;Jin, Xiaoping;Wang, Zhongmin Maxwell;Li, Baiyong;Xia, Yu;Zhu, Jun |
| 2019 |
Primary breast diffuse large B-cell lymphoma in the rituximab era: therapeutic strategies and patterns of failure (vol 109, pg 3943, 2018) |
Hu, Shaoxuan;Song, Yuqin;Sun, Xiuhua;Su, Liping;Zhang, Wei;Jia, Jing;Bai, Ou;Yang, Sheng;Liang, Rong;Li, Xiaoling;Zhang, Huilai;Gao, Yuhuan;Zhang, Weijing;Xiao, Xiubin;Bao, Huizheng;Wang, Ningju;Ren, Hanyun;Cen, Xinan;Yang, Shun'e;Zhao, Yu;Wang, Yinan;Wang, Yalan;Liu, Aichun;Wang, Jingwen;Shi, Yuankai;Yuan, Ming;Li, Yufu;He, Xiaohui |
